While interest grows around the world for the design of vaccines, an IRIC team is getting closer and closer to a therapeutic cancer vaccine. The team headed by Dr. Claude Perreault couldn’t have imagined that by sorting through “junk DNA” it would find the ingredient for a unique therapy that could one day transform the lives of thousands of patients.

To develop a first vaccine intended for humans, these scientists first target ovarian cancer and acute myeloid leukemia, two types of cancer for which the patient survival rate could be significantly improved.

Clinical studies should get underway within three years; that’s a hope that leaves no one indifferent.